Charl van Zyl, Lundbeck CEO
October 14, 2024 07:20 AM EDTUpdated 10:13 AM
Deals
Pharma

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Kyle LaHucik

Senior Reporter

Dan­ish drug­mak­er Lund­beck will buy La Jol­la, CA-based Long­board Phar­ma­ceu­ti­cals for $2.6 bil­lion in cash, the com­pa­nies said Mon­day morn­ing, mark­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times